Form 4: TOI 10% owner buys 27,429 shares at $2.96

Oncology Institute (TOI) 10% owner Jorey Chernett reported an open-market purchase of 27,429 shares at $2.96, increasing direct holdings to 10,479,358 shares.

Summary

• 10% owner Jorey Chernett purchased 27,429 shares of Oncology Institute, Inc. (TOI) on 03/27/2026.
• Transaction type: Open-market purchase (Code P) at an average price of $2.96 per share.
• Post-transaction direct beneficial ownership: 10,479,358 common shares.
• Implied transaction value: approximately $81,197.84.
• Incremental increase in stake: ~0.26% versus post-transaction holdings.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a modestly positive signal due to insider buying by a 10% owner, though the purchase size is small relative to total holdings.

Positives

• Insider buying: 10% owner increased holdings by 27,429 shares at $2.96, bringing total direct ownership to 10,479,358 shares.
• Open-market purchase signals direct capital commitment by a large shareholder.

Negatives

• No information provided on company operating performance, profitability, or strategy in this disclosure.

Future Outlook

No forward-looking statements or guidance provided.

Industry Context

StockSavvy.ai notes that insider open‑market purchases at healthcare services companies are commonly interpreted as a modestly constructive signal of alignment, though single transactions—especially small relative to total ownership—should be weighed cautiously alongside fundamentals and upcoming catalysts.

Comparison to Industry Standards

• Insider open-market purchases are broadly viewed positively across healthcare providers but are not directly comparable to operating benchmarks reported by peers such as Encompass Health, DaVita, or RadNet; this disclosure does not include operational or financial KPIs.
• The purchase (~$81k) is modest relative to typical material insider transactions that can exceed several hundred thousand to multi‑million dollars; as such, signal strength is limited without corroborating operational data.

Stakeholder Impact

• Shareholders: Incremental insider buying may be viewed as alignment with investor interests.
• Market liquidity/float: Minimal impact given small transaction size relative to total ownership.
• No direct effect disclosed for employees, customers, suppliers, or creditors.

Key Dates

Keywords

Oncology Institute, TOI, Form 4, insider buying, beneficial ownership, Jorey Chernett, open market purchase, 10% owner, healthcare services, oncology